Vir BiotechnologyNASDAQ: VIR

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Eric Joseph - JPMorgan Mike Ulz - Morgan Stanley Gena Wang - Barclays Alec Stranahan - Bank of America Nikola Gasic - Leerink Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors.

24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.

VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences.

Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company's Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. Dr. Eisner comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In.

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will hig.

Vir Biotechnology, Inc. (NASDAQ: VIR) Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET featured company executives Sasha Damouni Ellis, Marianne De Backer, Carrie Huang, and Sung Lee. Conference call participants included Gena Wang, Paul Choi, Alec Stranahan, Phil Nadeau, Patrick Trucchio, Rosa Chen, Joseph Stringer, Eric Joseph, and Michaels Ulz. The call was moderated by the operator who greeted everyone.

Vir Biotechnology, Inc. (VIR) reported a quarterly loss of $0.48 per share, which was lower than the expected loss of $0.99 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $1.06 per share reported in the same quarter last year.